Director/PDMR Shareholding
Summary by AI BETAClose X
Diaceutics PLC
Grant of Share Options/PDMR Shareholdings
New York, Belfast and London, 12 November 2026 - Diaceutics PLC (AIM: DXRX), the intelligence and engagement company unlocking the full potential of diagnostic-driven therapies, announces the grant of 976,744 share options over ordinary shares of £0.002 each in the Company (“Share Options”) to certain directors and members of the Company’s senior management team on 23 October 2026, pursuant to the Company’s Employee Share Option Plan (“ESOP”). These awards are made in accordance with the Company’s long term incentive plan as detailed in the Company’s Annual Report.
Share Options were granted as follows:
|
Name |
Number of Share Options granted |
Total no. of ordinary shares under option post grant |
% of existing issued share capital |
Performance Period |
|
Ryan Keeling, CEO
|
301,625 |
1,640,923 |
1.92% |
3 years from 30 July 2026 |
|
Nick Roberts, CFO |
195,861 |
815,196 |
0.96% |
3 years from 30 July 2026 |
|
Jordan Clark, CCO
|
191,508 |
521,005 |
0.61% |
3 years from 30 July 2026 |
|
Sandra Blake, CMPO and PDMR |
93,144 |
255,730 |
0.30% |
3 years from 30 July 2026 |
|
Chris Meenan, CPTO and PDMR |
106,668 |
106,668 |
0.13% |
3 years from 30 July 2026 |
|
Susanne Munksted, CPO and PDMR |
87,938 |
412,911 |
0.48% |
3 years from 30 July 2026 |
For the Executive Directors, Jordan Clark, Ryan Keeling and Nick Roberts, the Share Options vest on a sliding scale up to 100%, where vesting is subject to the satisfaction of certain performance criteria. The performance criteria are based upon the growth during the Performance Period in Total Shareholder Return (“TSR”), the revenue Compound Annual Growth Rate (“CAGR”) and Adjusted EBITDA Margin. For all other employees, the Share Options vest after three years from the date of grant dependent upon continual employment and satisfactory employee performance.
The Remuneration Committee will review the performance conditions at periodic intervals to ensure they remain appropriate. As a result of any such review, the Committee will retain discretion to amend the conditions where appropriate, having regard to overall Company performance and wider shareholder experience.
The exercise price of the Share Options is £0.002 per share which equates to the nominal value of the ordinary shares.
Following this grant, the total number of share options outstanding in the Company is 7,042,578 representing approximately 8.26% of its current issued share capital of 85,291,958.
Enquiries:
|
Diaceutics PLC |
|
|
Ryan Keeling, Chief Executive Officer |
Tel: +44 (0)28 9040 6500 |
|
Nick Roberts, Chief Financial Officer |
investorrelations@diaceutics.com |
|
|
|
|
Canaccord Genuity Limited (Nomad & Broker) |
Tel: +44 (0)20 7253 8000 |
|
Simon Bridges, Andrew Potts, Harry Rees |
|
|
|
|
About Diaceutics
At Diaceutics, our mission is to redefine commercialization for diagnostic-driven therapies, so every eligible patient is found, diagnosed and receives the right therapy at the right time. Since 2005, we have combined diagnostic intelligence, expert insight and targeted engagement to help biopharma teams see where patients are being missed and close the gaps between testing, treatment decisions and therapy adoption. Today, we work with 21 of the top 30 pharma companies, and the therapies we support touch 1 in 10 American lives. We envision a future where precision is not the privilege of the few, but the standard for all.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 hour ago Frasers Group
- 1 hour ago Cavendish Financial
- 1 hour ago Diaceutics
- 1 hour ago AB Dynamics
- 15 hours ago Johnson Matthey